Open access

726 Establishing proof of mechanism in patients: preliminary biomarker data of SRK-181 (a latent TGFβ1 inhibitor) from DRAGON Study
Susan Henry, Stephen DeWall, Ulka N Vaishampayan, Amna Sher, Ahmad A Tarhini, Deepak Kilari, Randy Sweis, Timothy Yap, Justin Gainor, Minal Barve, John Clark, Lan Liu, Asia McCune, Yawen Ju, Mo Qatanani, Lu Gan

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A821; DOI: 10.1136/jitc-2023-SITC2023.0726
727 Topline safety and efficacy update of SUPLEXA-101, a first-in-human, single agent study of SUPLEXA therapeutic cells in 28 patients with metastatic solid tumours
Rohit Joshi, Jeffrey Goh, Sharron Gargosky, Ganessan Kitchenadasse, Victoria Atkinson, Warren Joubert, Vineet Kwatra, Meena Okera, Sarwan Bishnoi, George Nisyrios, James A Lederer, Frank Borriello

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A822; DOI: 10.1136/jitc-2023-SITC2023.0727
728 A phase 1/2 study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, in patients with advanced solid tumors
Nuria Kotecki, Sylvie Rottey, Brant Delafontaine, Elena Garralda, Vladimir Galvao, Maria de Miguel, Omar Saavedra, Valentina Boni, Amanda McEwen, Shalabh Singhal, Samuel L Murphy, Naimish Pandya

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A823; DOI: 10.1136/jitc-2023-SITC2023.0728
729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
Jeeyun Lee, Byoung Chul Cho, Jae Lyun Lee, Jung-Yun Lee, Jian L Campian, Yujie Zhao, Mahesh Seetharam, Alex A Adjei, Wen Wee Ma, Dongwoo Chae, Nari Yun, Woosun Lee, Wooyul Lee, Sosun Park, Bochan Seo, Kyungwha Lee, Chong Woo Park, Myoung Ho Jang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A824; DOI: 10.1136/jitc-2023-SITC2023.0729
730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors
Daneng Li, Alexander I Spira, Hirva Mamdani, Jennifer Leddon, Yuman Fong, Leslie Chong, Seymour Fein, Nick Ede, Ursula McCurry, Amanda Seiz, Melissa Polasek, Sharon Yavrom, Giovanni Selvaggi

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A825; DOI: 10.1136/jitc-2023-SITC2023.0730
732 Immune activation with plinabulin enhances anti-tumor response combining radiation with immune checkpoint blockade
Steven H Lin, Evan Cohen, Ziyi Li, James Reuben, Hui Gao, Huiying Sun, June Lu, Ken Lloyd, James Tonra, Lan Huang, Siqing Fu, Vivek Subbiah

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A826; DOI: 10.1136/jitc-2023-SITC2023.0732
733 Phase 1 study of ultra-high concentration nitric oxide ablation in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies
Amichay Meirovitz, David Greenberg, Amir Avniel, Gavin Choy, Jedidiah Monson

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A827; DOI: 10.1136/jitc-2023-SITC2023.0733
735 Peripheral and tissue persistence of agenT-797, an allogeneic iNKT cell-based cell therapy for the treatment of cancer
Jamie Moon, Sue Ryu, Irene R Ramos, Benjamin Garmezy, John Hamm, Benedito Carneiro, Trisha M Wise-Draper, Breelyn Wilky, Rachel E Sanborn, Anthony El-Khoueiry, Marco A Purbhoo, Dave SB Hoon, Marc Van Dijk

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A828; DOI: 10.1136/jitc-2023-SITC2023.0735
736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies
Justin C Moser, Ryan Sullivan, Matthew H Taylor, Igor Puzanov, Gerald S Falchook, Mario Sznol, Virginia E Paton, David Chonzi, Brage Garofalo, Mark Sonnemann, Hirdesh Uppal, Jeremy Barton, Beatrice Y McQueen, Aaron M Ring, Harriet Kluger

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A829; DOI: 10.1136/jitc-2023-SITC2023.0736
737 A phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in patients with immunotherapy-sensitive locally advanced or metastatic solid tumors
Justin C Moser, Mateusz Opyrchal, Ildefonso Rodriguez Rivera, Mehmet A Bilen, Brendan Curti, Igor Puzanov, Kristin Morris, Christopher J Nirschl, Saero Park, Marissa Bruno, Paul Windt, Kulandayan K Subramanian, Sameer S Chopra, Randi Isaacs

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A830; DOI: 10.1136/jitc-2023-SITC2023.0737

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages